No photo of Massimo Colombo

View Scopus Profile

Massimo Colombo

1972 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Massimo Colombo is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 48 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Elimination of hepatitis C in Europe: can WHO targets be achieved?

the ESCMID Study Group for Viral Hepatitis (ESGVH), Jan 1 2020, (Accepted/In press) In : Clinical Microbiology and Infection.

Research output: Contribution to journal › Review article

    • The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy

    Loglio, A., Iavarone, M., Facchetti, F., Di Paolo, D., Perbellini, R., Lunghi, G., Ceriotti, F., Galli, C., Sandri, M. T., Viganò, M., Sangiovanni, A., Colombo, M. & Lampertico, P., Jan 1 2020, (Accepted/In press) In : Liver International.

    Research output: Contribution to journal › Article

    • Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance

    Iavarone, M., Viganò, M., Piazza, N., Occhipinti, V., Sangiovanni, A., Maggioni, M., D'Ambrosio, G., Forzenigo, L. V., Motta, F., Lampertico, P., Rumi, M. G. & Colombo, M., Mar 1 2019, In : Annals of Hepatology. 18, 2, p. 318-324 7 p.

    Research output: Contribution to journal › Article

    • Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance

    Iavarone, M., Viganò, M., Piazza, N., Occhipinti, V., Sangiovanni, A., Maggioni, M., D'Ambrosio, G., Forzenigo, L. V., Motta, F., Lampertico, P., Rumi, M. G. & Colombo, M., Mar 1 2019, In : Annals of Hepatology. 18, 2, p. 318-324 7 p.

    Research output: Contribution to journal › Article

    Open Access

    • Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

    Merle, P., Blanc, J. F., Phelip, J. M., Pelletier, G., Bronowicki, J. P., Touchefeu, Y., Pageaux, G., Gerolami, R., Habersetzer, F., Nguyen-Khac, E., Casadei-Gardini, A., Borbath, I., Tran, A., Wege, H., Saad, A. S., Colombo, M., Abergel, A., Richou, C., Waked, I., Yee, N. S. & 30 others, Molé, A., Attali, P., Le Boulicaut, J., Vasseur, B., Moussata, D., Grangé, J. D., Ratziu, V., Khemissa-Akouz, F., Regnault, H., Dauvois, B., Zarski, J. P., Ollivier-Hourmand, I., Manfredi, S., Debette-Gratien, M., Gangloff, A., Fontanges, T., Baron, A., Bouattour, M., Vincent, J., Sieghart, W., Maieron, A., Peeters, M., Delwaide, J., Lasser, L., Berg, T., Schultheiß, M., Zipprich, A., Trojan, J., Ehmer, U. & Buonadonna, A., Jun 1 2019, In : The Lancet Gastroenterology and Hepatology. 4, 6, p. 454-465 12 p.

    Research output: Contribution to journal › Article